RECORD // Company

Ocular Therapeutix, Inc

Formerly: I-THERAPEUTIX INC

Built 2026-11-21T11:39:44Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (7)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Ocular Therapeutix, Inc. · Ctgov · same registered legal name as 'OCULAR THERAPEUTIX, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • OCULAR THERAPEUTIX, INC. · East licences · same registered legal name as 'OCULAR THERAPEUTIX, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • OCULAR THERAPEUTIX, INC. · East licences · same registered legal name as 'OCULAR THERAPEUTIX, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • OCULAR THERAPEUTIX, INC. · East licences · same registered legal name as 'OCULAR THERAPEUTIX, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • OCULAR THERAPEUTIX INC · Epa echo · same registered legal name as 'OCULAR THERAPEUTIX, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • OCULAR THERAPEUTIX, INC. · Ny corps · same registered legal name as 'OCULAR THERAPEUTIX, INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • OCULAR THERAPEUTIX, INC · USAspending · same registered legal name as 'OCULAR THERAPEUTIX, INC' Possible match based on name, not a shared identifier. Compare the records. Compare

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001104659-26-124155

ItemValuePeriodFormFiledAccessionReport
Revenue$12,874,0003 months ended 2026-09-3010-Q2026-11-090001104659-26-1241552026-11-21 11:39 UTCReport an error
Net income (loss)$-94,782,0003 months ended 2026-09-3010-Q2026-11-090001104659-26-1241552026-11-21 11:39 UTCReport an error
Interest expense$2,814,0003 months ended 2026-09-3010-Q2026-11-090001104659-26-1241552026-11-21 11:39 UTCReport an error
Cash and cash equivalents$530,612,000at 2026-09-3010-Q2026-11-090001104659-26-1241552026-11-21 11:39 UTCReport an error
Contract liabilities (total)$14,000,000at 2026-09-3010-Q2026-11-090001104659-26-1241552026-11-21 11:39 UTCReport an error
Contract liabilities, noncurrent$14,000,000at 2026-09-3010-Q2026-11-090001104659-26-1241552026-11-21 11:39 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001393434
Ticker
OCUL
CUSIP
67576A100
Record ID
sx:sec:0001393434

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-10SEC EDGAR company profile2026-11-21 11:39 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-10SEC EDGAR company profile2026-11-21 11:39 UTCReport an error
State of incorporationDE2026-11-10SEC EDGAR company profile2026-11-21 11:39 UTCReport an error
Fiscal year end (MMDD)12312026-11-10SEC EDGAR company profile2026-11-21 11:39 UTCReport an error
Business address14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 017302026-11-10SEC EDGAR company profile2026-11-21 11:39 UTCReport an error
ExchangesNasdaq2026-11-10SEC EDGAR company profile2026-11-21 11:39 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$51,951,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:39 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-265,939,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:39 UTCReport an error
Total assets (at 2025-12-31)$808,057,0002025-12-3110-K, XBRL Assets2026-11-21 11:39 UTCReport an error
Stockholders' equity (at 2025-12-31)$654,310,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:39 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$737,060,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:39 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-204,883,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:39 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$12,010,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:39 UTCReport an error
Operating lease liabilities (at 2025-12-31)$5,632,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:39 UTCReport an error
Form D total offering amount (D filed 2019-03-18)$37,500,0002019-03-18D2026-11-21 11:39 UTCReport an error
Form D total amount sold (D filed 2019-03-18)$37,500,0002019-03-18D2026-11-21 11:39 UTCReport an error
Form D industry groupBiotechnology2019-03-18D2026-11-21 11:39 UTCReport an error
Form D revenue rangeDecline to Disclose2019-03-18D2026-11-21 11:39 UTCReport an error
Form D date of first sale2019-03-012019-03-18D2026-11-21 11:39 UTCReport an error
8-K Item 5.02 (filed 2026-11-09)Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Riad Sherif, M.D. On November 6, 2026, the Board of Directors (the “Board”) of Ocular Therapeutix, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Riad Sherif, M.D., to serve as a member of the Board, effective immediately. Dr. Sherif was designated as a Class I member of the Board to serve until the Company’s 2027 annual meeting of stockholders and thereafter until his successor is duly elected and qualified, or until his earlier death, resignation or…2026-11-09SEC EDGAR 8-K 0001104659-26-124159 (text as filed, excerpt)2026-11-21 11:39 UTCReport an error
8-K Item 2.02 (filed 2026-11-09)Results of Operations and Financial Condition. On November 9, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any…2026-11-09SEC EDGAR 8-K 0001104659-26-124151 (text as filed, excerpt)2026-11-21 11:39 UTCReport an error
8-K Item 5.02, Departure (filed 2026-10-16)of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the “Company”), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.2026-10-16SEC EDGAR 8-K 0001104659-26-116617 (text as filed, excerpt)2026-11-21 11:39 UTCReport an error
8-K Item 2.02 (filed 2026-08-03)Results of Operations and Financial Condition. On August 3, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing…2026-08-03SEC EDGAR 8-K 0001104659-26-089443 (text as filed, excerpt)2026-11-21 11:39 UTCReport an error
Largest institutional holder #1 (13F as filed): FMR LLC$322,528,4992026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error
Largest institutional holder #2 (13F as filed): Deep Track Capital, LP$193,319,2892026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$190,277,7722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error
Largest institutional holder #4 (13F as filed): Avoro Capital Advisors LLC$123,142,8002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error
Largest institutional holder #5 (13F as filed): Summer Road LLC$119,885,4662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error
Largest institutional holder #6 (13F as filed): Venrock Adviser, LLC$101,606,8132026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$86,736,0832026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error
Largest institutional holder #8 (13F as filed): Logos Global Management LP$52,046,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error
Largest institutional holder #9 (13F as filed): STATE STREET CORP$51,390,8292026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error
Largest institutional holder #10 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$49,315,1152026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:39 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.